-
Neuralstem Updates NSI-189 Major Depression Trial
Monday, June 20, 2011 - 10:01am | 105Advancing to Final Phase Ia Cohort Neuralstem, Inc. (NYSE: CUR) announced that it has been approved to dose the final cohort in the ongoing Phase Ia trial to test the safety of NSI-189 for the treatment of major depression. Phase Ia is testing the drug in healthy volunteers for safety and...
-
Biogen Idec Trading Higher on ISI Group Upgrade
Monday, June 20, 2011 - 9:52am | 60Biogen Idec (NASDAQ: BIIB) is trading over 4% higher after ISI Group group upgraded the company to Buy. The shares of BIIB are currently trading at $99.06. Biogen Idec Inc., a biotechnology company, discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology,...
-
Rodman & Renshaw Raises PT On ADVENTRX Pharmaceuticals To $16
Monday, June 20, 2011 - 8:58am | 28Rodman & Renshaw has raised the price target on ADVENTRX Pharmaceuticals (AMEX: ANX) from $4.50 to $16 and maintains its Market Outperform rating.
-
Pluristem up Over 10% After Announcing Agreement with United Therapeutics Corporation
Monday, June 20, 2011 - 8:56am | 167Pluristem Ltd. (Nasdaq: PSTI) entered into an Exclusive License Agreement with United Therapeutics Corporation, for the use of Pluristem's PLacental eXpanded cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension. Under the terms of the Agreement,...
-
High-Flying Trade Setups 4 Longs & 4 Shorts
Monday, June 20, 2011 - 8:51am | 144There is a lot to be decided this week, from the FOMC, to the Greek debt crisis, to a market being so oversold, when will is finally muster a bounce? With that being said, the market could take a turn in either direction and for that, it is worth being prepared for the week ahead with 4 long setups...
-
J.P. Morgan Reiterates Overweight Rating On Ariad Pharmaceuticals
Monday, June 20, 2011 - 8:31am | 89According to J.P. Morgan, Ariad Pharmaceuticals (NASDAQ: ARIA) Overweight rating is reiterated. J.P. Morgan said that it reiterates its OW rating on ARIA following Friday's very well attended R&D Day in NYC. “While ARIA shares could be volatile (along with the rest of biotech) over the summer...
-
Benzinga's Top Pre-Market NASDAQ Losers
Monday, June 20, 2011 - 8:26am | 126Vitacost.com Inc (NASDAQ: VITC) dipped 61.40% to $2.20 in the pre-market session. Vitacost's common stock will resume trading on June 20 on the NASDAQ Global Market under the symbol “VITC”. Human Genome Sciences Inc (NASDAQ: HGSI) dropped 4.57% to $24 in the pre-market trading. HGSI's trailing-...
-
ISI Group Upgrades Biogen To Buy
Monday, June 20, 2011 - 8:18am | 17ISI Group has upgraded Biogen (NASDAQ: BIIB) to Buy.
-
Ligand Enters into Captisol Commercial Supply Agreement with Merck
Monday, June 20, 2011 - 8:03am | 76Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a Captisol® supply agreement with Merck & Co., Inc. (NYSE: MRK) for an undisclosed program. Ligand will supply clinical and commercial supplies of Captisol and, if the program is approved for...
-
Icagen and Pfizer Initiate Nav 1.7 Phase I Multiple Ascending Dose Study
Monday, June 20, 2011 - 8:03am | 227Icagen, Inc. (Nasdaq: ICGN) today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. Icagen and Pfizer have initiated a multiple ascending dose study of the lead compound in the collaboration, which targets the ion...
-
Piper Jaffray Reiterates Overweight Rating On Regeneron
Monday, June 20, 2011 - 7:51am | 93According to Piper Jaffray, Regeneron Pharmaceuticals (NASDAQ: REGN) Overweight rating is reiterated. Piper Jaffray said that on Friday, an FDA Advisory Committee voted unanimously 10-to-0 recommending approval of EYLEA (VEGF Trap-Eye) in Age-related Macular Degeneration (AMD). “We reiterate our...
-
Piper Jaffray Overweight On Amylin Pharmaceuticals
Monday, June 20, 2011 - 7:46am | 174Piper Jaffray has an Overweight rating and a $20 price target on shares of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). In a note to clients, Piper Jaffray writes, "We believe expectations for AMLN remain low and provide an opportunity for investors without taking on regulatory risk. Our webinar...
-
Wedbush Reiterates PT, Rating On MNTA
Monday, June 20, 2011 - 7:43am | 169Wedbush is reiterating its $27 price target and its Outperform rating on Momenta Pharmaceuticals (NASDAQ: MNTA) after a judge sided with TEVA in his recent decision. Says Wedbush, of the hearing, “On Friday June 17, 2011, a Federal Judge in the Southern District of New York denied a summary...
-
GTx Initiates Phase IIb Clinical Trial Evaluating Oral Capesaris
Monday, June 20, 2011 - 7:00am | 42GTx, Inc. (Nasdaq: GTXI), announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.
-
JP Morgan Raises PT On Ariad Pharmaceuticals To $13
Monday, June 20, 2011 - 6:49am | 27JP Morgan has raised the price target on Ariad Pharmaceuticals (NASDAQ: ARIA) from $10 to $13 and maintains its Overweight rating.